Brief Title: Avelumab Program Rollover Study

PRIMARY OUTCOMES

Primary Outcome 1 - Measure:

Primary Outcome 1 - Timeframe: N/A

CONDITION

• Solid Tumors

ELIGIBILITY

Inclusion Criteria:
* Participants under enrollment and treatment in an avelumab clinical study under the sponsorship of EMD Serono Research & Development Institute, Inc. / Merck KGaA, Darmstadt, Germany
* Merck Serono Co., Ltd (Japan)

- * Participants currently enrolled in an avelumab parent study and are on active treatment with avelumab or in long-term survival follow-up after treatment

- * Participants on active treatment must agree to continue to use highly effective contraception (that is, methods with a failure rate of less than 1% per year) for both male and female participants if the risk of conception exists

- * Other protocol defined inclusion criteria could apply.
Exclusion Criteria:
* Participants who are pregnant or breastfeeding

- * Participants still on active treatment: Known hypersensitivity to any of the study intervention ingredients

- * Participant has been enrolled in the comparator arm of avelumab parent study

- * Participant has been withdrawn from avelumab parent study for any reason

- * Any other reason that, in the opinion of the Investigator, precludes the participant from participating in the study

- * Other protocol defined exclusion criteria could apply.

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: Medical Responsible

Role: Study Director

Affiliation: Merck KGaA, Darmstadt, Germany

Overall Contact

Name: N/A

Phone: N/A

Email: N/A

LOCATION